Komatsubara Kazuo, Miyoshi Kyoko, Kogure Yuuki, Matsuhisa Tetsuaki, Eguchi Hisae
Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, Japan.
Gan To Kagaku Ryoho. 2010 Jan;37(1):107-10.
Paclitaxel (PTX) is one of the most important breast cancer treatment drugs. However, severe hypersensitivity reactions such as decreases in blood pressure and impaired breathing occur with high frequency. For the prevention of such hypersensitivity reactions, administration of a premedication composed of three components, diphenhydramine, ranitidine (or famotidine), and dexamethasone, has been advised in package insert information of medicine. Administration of diphenhydramine is difficult in breast cancer patients complicated with closed-angle glaucoma, because diphenhydramine has a weak anticholinergic adverse effect which can induce mydriasis and glaucoma attack. We studied the prevention of severe hypersensitivity reactions and of glaucoma attack in 2 breast cancer patients complicated with closed angle glaucoma at our hospital from April 2007 to March 2008. We switched from diphenhydramine to fexofenadine as the medicine to prevent hypersensitivity reactions. Hypersensitivity reactions were not observed throughout all courses in both patients, and no glaucoma attack was observed.
紫杉醇(PTX)是最重要的乳腺癌治疗药物之一。然而,严重的过敏反应,如血压下降和呼吸功能受损,却频繁发生。为预防此类过敏反应,药品说明书建议使用由苯海拉明、雷尼替丁(或法莫替丁)和地塞米松三种成分组成的预处理药物。对于合并闭角型青光眼的乳腺癌患者,使用苯海拉明存在困难,因为苯海拉明具有较弱的抗胆碱能不良反应,可诱发瞳孔散大和青光眼发作。2007年4月至2008年3月,我们在我院对2例合并闭角型青光眼的乳腺癌患者进行了严重过敏反应及青光眼发作预防的研究。我们将预防过敏反应的药物从苯海拉明换成了非索非那定。两名患者在所有疗程中均未观察到过敏反应,也未观察到青光眼发作。